SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Vasomedical Inc.
VASO 0.1700.0%Jan 2 9:30 AM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Michael Yang who wrote (256)1/22/1997 9:51:00 PM
From: Francois H. Gaston   of 1605
 
Michael:

1) rise.. buying opportunity... not for me because I would like to see great volume increase with it... not this low volume. On the other hand, study results may be leaking... but VASO has had many legs up in the past, without serious news... so I remain on the sideline.
2) only one in 10 patients enrolled. That is a rumor we got on the web.. the explanation being that they are trying to get a uniform group of patients (sick enough, but not too sick; not with recent angina (which can improve on its own) but with chronic angina... so many patients are scrrend an rejected.
3) for which patients will be EECP useful (if study is very positive)... MANY... for example all patients scheduled for PTCA o CABG should be screened for EECP before sending them to PTCA (only 70% success at 6 months) or CABG (1-2% death...)... and patients who want to reduce their drugs, or who want to try to be more active...

Those are my thoughts at this time.

FHG
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News